Trial Profile
An Open Label, Multi-Center Study Evaluating the Safety of Long-Term Inhaled Treprostinil Sodium Administration Following Transition From Inhaled Ventavis (Iloprost) in Subjects With Pulmonary Arterial Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- 10 Feb 2012 Actual patient number is 73 according to ClinicalTrials.gov.
- 10 Feb 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 10 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.